Janssen (J&J) COVID Vaccine to Resume in the United States
April 26, 2021
Dear Colleague:
After a thorough safety review, the U.S. Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) have determined that the use of Janssen (J&J) COVID vaccine should resume in the United States. As such, the Georgia Department of Public Health (DPH) COVID Vaccine Program will again offer J&J vaccine to Georgians aged 18 and older.
A warning will be added to the J&J vaccine about the potential for very rare, but severe blood clots associated with the vaccine. Vaccine providers administering the J&J vaccine should review the Janssen COVID-19 Vaccine Fact Sheet. Vaccine recipients and/or their caregivers should be provided with the Janssen COVID-19 Vaccine Fact Sheet for Recipients and Caregivers. Both fact sheets now include information about thrombosis and thrombocytopenia syndrome which have occurred in a very small number of people who have received the J&J vaccine.
|